{"entity":{"id":"gerhardt-attard","kind":"person","name":"Gerhardt Attard","aka":[],"tldr":"London oncologist who helped develop abiraterone and led the STAMPEDE analysis showing that two years of abiraterone alongside hormone therapy and radiotherapy improves survival in high-risk localised prostate cancer.","summary":"Gerhardt Attard is a medical oncologist at the UCL Cancer Institute who worked on the early clinical development of abiraterone at The Institute of Cancer Research. He was first author of the 2022 Lancet report of the STAMPEDE platform's combined analysis, which showed that adding abiraterone (with or without enzalutamide) to androgen deprivation therapy improved metastasis-free and overall survival in high-risk non-metastatic prostate cancer. His laboratory studies androgen receptor genomics and plasma DNA in prostate cancer.","asOf":"2026-09-18","links":[],"tags":["prostate","trialist"],"related":[],"cancers":["prostate-high-risk","prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["uclh"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-stampede-abiraterone-high-risk-attard-lancet-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist, UCL Cancer Institute and University College London Hospitals","institutionId":"uclh","specialisms":["Prostate cancer","Androgen receptor signalling","Circulating tumour DNA"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Attard%5BAuthor%5D"}],"papers":[],"orcid":"0000-0002-4811-7983"},"route":"/people/gerhardt-attard/","neighbours":{"cancer":[{"id":"prostate-high-risk","kind":"cancer","name":"Localised prostate cancer, high and very high risk","route":"/cancers/prostate-high-risk/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"institution":[{"id":"uclh","kind":"institution","name":"University College London Hospitals / UCL Cancer Institute","route":"/institutions/uclh/"}],"paper":[{"id":"paper-stampede-abiraterone-high-risk-attard-lancet-2022","kind":"paper","name":"STAMPEDE: abiraterone with or without enzalutamide added to androgen deprivation for high-risk non-metastatic prostate cancer","route":"/key-papers/paper-stampede-abiraterone-high-risk-attard-lancet-2022/"}]}}